B
Brandon Luber
Researcher at Johns Hopkins University
Publications - 49
Citations - 24678
Brandon Luber is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Prostate cancer & Enzalutamide. The author has an hindex of 26, co-authored 49 publications receiving 19451 citations. Previous affiliations of Brandon Luber include Johns Hopkins University School of Medicine & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
Risk Factors for Progression of Barrett's Esophagus to High Grade Dysplasia and Esophageal Adenocarcinoma
TL;DR: Low-grade dysplasia was a risk factor for progression but various endoscopic characteristics were not, suggesting that screening strategies should focus on histology instead, and SSRIs were identified as a new potentially chemoprotective medication.
Journal ArticleDOI
From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting
Steven P. Rowe,Brandon Luber,Monique Makell,Jo Ann Santmyer,Megan D. Schollenberger,Hannah Quinn,Daniel L. Edelstein,Frederick S. Jones,Karen B. Bleich,William H. Sharfman,Evan J. Lipson +10 more
TL;DR: In four of 30 patients with advanced melanoma, ctDNA assessments indicated evidence of melanoma activity that predicted radiographic evidence of disease progression by 8, 14, 25, and 38 weeks, respectively.
Journal ArticleDOI
Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).
Emmanuel S. Antonarakis,Changxue Lu,Hao Wang,Brandon Luber,Mary Nakazawa,Yan Chen,Jeffrey C. Roeser,Helen L. Fedor,Tamara L. Lotan,Qizhi Zheng,Angelo M. De Marzo,John T. Isaacs,William B. Isaacs,Rosa Nadal,Channing J. Paller,Samuel R. Denmeade,Michael A. Carducci,Mario A. Eisenberger,Jun Luo +18 more
TL;DR: Associations between AR-V7 status and PSA response rates, PSA progression-free survival (PSA-PFS), and clinical/radiographic progression- free survival (PFS) are examined.
Journal ArticleDOI
AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).
Emmanuel S. Antonarakis,Changxue Lu,Yan Chen,Brandon Luber,Hao Wang,Mary Nakazawa,Angelo M. De Marzo,William B. Isaacs,Rosa Nadal,Channing J. Paller,Samuel R. Denmeade,Michael A. Carducci,Mario A. Eisenberger,Jun Luo +13 more
TL;DR: It is hypothesized that AR-V7[+] patients would retain sensitivity to taxane chemotherapy and associations between AR-v7 status and PSA response rates, PSA progression-free survival (PSA-PFS), and clinical/radiographic progression- free survival (PFS) are sought.
Journal ArticleDOI
Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.
Nicolas J. Llosa,Nicolas J. Llosa,Brandon Luber,Brandon Luber,Nicholas Siegel,Nicholas Siegel,Anas H. Awan,Anas H. Awan,Teniola Oke,Teniola Oke,Qingfeng Zhu,Qingfeng Zhu,Bjarne Bartlett,Bjarne Bartlett,Bjarne Bartlett,Laveet K. Aulakh,Laveet K. Aulakh,Laveet K. Aulakh,Elizabeth D. Thompson,Elizabeth D. Thompson,Elizabeth M. Jaffee,Elizabeth M. Jaffee,Jennifer N. Durham,Jennifer N. Durham,Cynthia L. Sears,Cynthia L. Sears,Dung T. Le,Dung T. Le,Dung T. Le,Luis A. Diaz,Luis A. Diaz,Drew M. Pardoll,Drew M. Pardoll,Hao Wang,Hao Wang,Franck Housseau,Franck Housseau,Robert A. Anders +37 more
TL;DR: A composite score utilizing tumor PD-L1 expression and mucin content, the CPM score, was defined in patients with metastatic colorectal cancer, which distinguished patients who achieved clinical benefit with anti–PD-1 from those who developed progressive disease.